摘要
目的:探讨黄芪甲苷能否抑制Hela细胞的增殖和侵袭迁移能力,并初步探讨相关机制。方法:选取人宫颈癌Hela细胞,0、0.2、0.4、0.8、1.6、3.2 mg/ml黄芪甲苷作用于细胞,通过CCK-8和平板克隆形成实验探讨该药物对Hela细胞增殖能力的影响;通过Transwell细胞迁移和侵袭实验研究黄芪甲苷对Hela细胞侵袭迁移能力的影响;通过Western Blot检测肿瘤侵袭、迁移相关蛋白MMP2、MMP9的表达情况。结果:0.2mg/ml以上黄芪甲苷对Hela细胞增殖能力具有显著抑制作用,存在浓度-时间依赖性;0.2mg/ml黄芪甲苷处理Hela细胞24、48 h后,穿过小室的细胞数均明显减少;0.2mg/ml黄芪甲苷对肿瘤侵袭和迁移相关蛋白MMP2、MMP9的表达水平均显著下降。结论:黄芪甲苷可抑制Hela细胞的增殖和细胞迁移侵袭的能力,其抑制作用可能和Hela细胞MMP 2、MMP 9的表达下调有关。
Object： The present study investigated the effects of Astragaloside Ⅳ（AS-Ⅳ） on Hela cervical cancer cells and examined the underlying mechanisms preliminaryly that in order to provide a theoretical and experimental basis for the development of new drugs for cervical cancer.Methods： The inhibitory rate of the Hela cells was detected by CCK-8 assay after treatment with different doses（0,0. 2,0. 4,0. 8,1. 6,3.2 mg/ml） for 24,48,72 hours. Plate clonality assays was also used to measure the impact of cell density to cell clonality. The effects of ASⅣ（0. 2 mg/ml） on invasion,migration and metastasis were investigated by Transwell assays. In addition,protein expressions of matrix metallo proteases MMP2,MMP9 were detected by Western Blot. Results： AS-Ⅳ at different doses（0,0. 2,0. 4,0. 8,1. 6,3. 2 mg/ml） showed an inhibitory effect on the proliferation of Hela cells in a concentration-dependent and time-dependent manner. With the increase of concentration,the volume of clonal formation and the number were gradually decreased. Transwell assays showed that the low doses AS-Ⅳ（0. 2 mg/ml）could inhibit invasion and migration significantly. Western blotting assays showed that the expression of MMP2 and MMP9 were decreased after treated with low doses AS-Ⅳ for 48 hours. Conclusion： AS-Ⅳ inhibited the proliferation and invasive potential of Hela cells,and downregulated matrix metallo proteases MMP2 and MMP9.
作者
李文
旷雨
孟立峰
任黔川
Li Wen;Kuang Yu;Meng Lifeng;Ren Qianchuan(The Affiliated Hospital of Southwest Medical University,Department of Obstetrics and Gynecology;Combined Traditional Chinese and Western Medicine Laboratory for Controlling Organ Fibrosis,Southwest Medical University,Luzhou 646000;First Affiliated Hospital,Guan-gxi University of Traditional Chinese Medicine,State Administration of Traditional Chinese Medicine Key Specialty,Nanning 530023)
出处
《中药药理与临床》
CAS
CSCD
北大核心
2018年第3期39-42,192,共5页
Pharmacology and Clinics of Chinese Materia Medica
基金
中国博士后科学基金(2017M612987)
